Advertisement
Advertisement
TOPIC

China’s private sector

China’s private sector
The latest news, analysis and opinion on China’s private sector. In-depth analysis, industry insights and expert opinion.
Chinese biotech firms reached 157 agreements to out-licence early-stage drugs last year. Photo: Shutterstock
Biomedicine: Companies

How China’s ‘landmark’ drug pricing guidelines could be a boon for biotech

State Council calls for ‘value-based pricing’ for innovative drugs, a move researchers said would benefit private healthcare players.

Biomedicine: Companies

Chinese drug makers take on Western dominance in US$16 billion Parkinson’s race

Biomedicine: Companies

China’s drug makers are speeding up – will AI be their secret weapon?

United States

Chinese firms drawn to Brazil as they seek anchor for Latin America expansion

Chinese brands like Mixue, BYD, and Geely are surging into Brazil, leveraging strong trade ties and local strategies for growth.

Chinese ice cream and beverage chain Mixue opened its first Brazilian store in Sao Paulo, on April 11, 2026. Photo: Reuters
Mainland China

China’s tea-drink shops thirst for profits as price wars dry up prospects

‘I am learning a hard lesson of how involution can destroy my business,’ a Shanghai shop operator says.

Mainland China

Splashing out: how much would you expect to pay for LV’s latest quirky man bag?

Offbeat designs may not drive sales, but they sharpen brand identity and attract individuality-seeking buyers, analysts say.

Advertisement
Advertisement
Advertisement
Coffee

Chinese coffee brands need more than low prices to compete globally: analysts

Luckin, Lucky Cup, Cotti and Nowwa are expanding quickly overseas, but analysts warn success depends on consumer experience and quality.

A Luckin Coffee outlet in Manhattan, New York. Photo: Getty Images/AFP
Biomedicine: Industry Trends

Li Ka-shing’s CK Life unit eyes China fast track for cancer vaccine pipeline

Sequencio, CK Life’s new Hong Kong unit, is advancing about 20 cancer vaccine projects as China pathway offers faster route to human trials.

China manufacturing

BASF launches biggest overseas project in China with green-powered mega-site

German chemical giant opens US$10 billion Zhanjiang complex, its largest overseas investment, as Beijing courts foreign capital.

IPO

China’s Jiangsu Aidea eyes Hong Kong IPO as gateway to US, European Aids markets

Yangzhou-based drug maker views Hong Kong as a ‘good window’ for its international expansion in HIV and Aids treatments.

Liu Yan says Hong Kong has a flexible fundraising environment. Photo: Denise Tsang
Biomedicine: Industry Trends

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Semaglutide generated about US$35 billion in global revenue last year. Photo: AFP
Hong Kong

China Mobile bets on Hong Kong as gateway for global computing flows

China Mobile opens new data centre and expands cables as Hong Kong is drawn deeper into China’s national computing network.

Shenzhen

Visa-free travel, rising foreign visitors boost luxury hotel growth in China

China’s luxury hotels thrive as visa-free policies drive international tourism, with Shanghai and Beijing seeing significant growth in high-end stays.

videocam
Biomedicine: Companies

Rights to antibody drug from China’s Keymed change hands in US acquisition

Sichuan-based Keymed expects to receive up to US$320 million as a result of deal involving its autoimmune disease treatment licensed in 2024.

Gilead Sciences is one of many drug firms facing a revenue gap owing to expiring patents. Photo: Reuters
Artificial intelligence

OpenClaw, government support fuel rise of 1-person companies in China

Guangdong is the first provincial-level government to roll out comprehensive action plans to support AI-powered OPCs.

A setup session to install OpenClaw outside the Baidu offices in Beijing, March 17, 2026. Photo: Reuters
Shanghai

Shanghai certifies 30 overseas offices amid China’s investment sales pitch

The city welcomed a batch of new regional headquarters and R&D centres this week, as China continues its campaign to win back overseas capital.

Biomedicine: Companies

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

The move will bring the total cumulative investment of Eli Lilly in China to nearly US$6 billion. Photo: Reuters
Focus

Why China’s red-hot tech push is leaving some sectors out in the cold

Beijing’s preferences for innovation and emerging industries are affecting businesses’ development paths and reshaping the corporate landscape.

videocam
South Korea

From oil to saffron: how US-Iran conflict is rattling Chinese retail investors

Retail investors on Chinese platforms probe companies about supply-chain risks and opportunities as tensions escalate in the Middle East.

Artificial intelligence

Will users stick around after China’s US$1 billion AI marketing battle?

Vouchers, red packets and sponsorships drove a surge in AI users over Chinese New Year, but now the tech giants face a retention test.

Red-packet battle: AI tech giants spent a collective US$1 billion on marketing this Chinese New Year. Photo: Getty Images
Two Sessions 2026

How China could untangle its private firms’ complex debt burdens

As private businesses grapple with cash flow challenges, entrepreneurs say they want the settling of outstanding debts to be made a priority.

Workers install insulation on a residential building under construction in Beijing in December. Photo: AP
Retailing

Warm winter no match: China’s sportswear sector posts surprise growth

Policy support, Chinese New Year demand and Winter Olympics exposure lift China’s sportswear makers, with Li Ning and Anta leading gains.

Biomedicine: Companies

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Electric & new energy vehicles

Speed bump ahead: rising battery costs nudge Chinese drivers towards hybrids

Higher lithium prices and the end of incentives are reshaping China’s EV market, with hybrids emerging as a more practical option for many.

6
Workers produce lithium batteries in Qinyang, central China’s Henan province. Photo: Xinhua
Biomedicine: Industry Trends

Lab monkey price tag climbs to US$20,000 thanks to China’s biotech boom

The cost of a single monkey exceeds the average annual salary in China and approaches a pandemic-era spike amid growth in drug licensing deals.

Founder Securities expects the annual domestic supply of experimental monkeys in China to range between 49,000 and 52,400 animals from 2025 to 2027. Photo: Shutterstock
China energy security

Chinese power line projects seek private capital in sign of infrastructure shift

Beijing is encouraging more private investment in a range of critical infrastructure projects, from railways to nuclear power plants.

videocam
China’s crackdowns

China charges former AstraZeneca executive – a sign of the times?

Foreign drug makers face pressure in the Chinese market, from tighter regulatory oversight to growing local competition.

Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement